Last reviewed · How we verify
NCT07053735
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
Phase 1 trial testing Nimotuzumab and Radiotherapy in Bladder (Urothelial, Transitional Cell) Cancer in 30 participants. Not yet recruiting.
30 June 2027
Quick facts
| Lead sponsor | Peking University First Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 30 June 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
Drugs / interventions tested
- Nimotuzumab and Radiotherapy — full drug profile →
Conditions studied
- Bladder (Urothelial, Transitional Cell) Cancer — all drugs for Bladder (Urothelial, Transitional Cell) Cancer →
Sponsor
Peking University First Hospital
Who can join
18 and older, any sex, with Bladder (Urothelial, Transitional Cell) Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this exploratory study is to evaluate the safety and efficacy of nimotuzumab combined with chemoradiotherapy in bladder - preserving treatment for MIBC patients who are ineligible for or decline radical cystectomy. The main questions it aims to answer are: Does nimotuzumab combined with radiotherapy reduce adverse events in elderly bladder cancer patients? Does this combination improve objective response rate (ORR), progression - free survival (PFS), overall survival (OS), and bladder preservation rate in these patients? Participants will be MIBC patients treated with nimotuzumab and chemoradiotherapy, with a planned 5 - year follow - up to assess treatment efficacy and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07053735
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder (Urothelial, Transitional Cell) Cancer
Currently open trials in the same condition.
- NCT07589413 — Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT · recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06787053 — Selecting Hypoxic Tumours for Treatment Modification · recruiting
- NCT06696742 — PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma · Phase 2 · recruiting
Other Peking University First Hospital trials
Trials by the same sponsor.
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
- NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07053735 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07053735.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing